PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870495] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
 Protocol for Safety Use of Antipsychotics in Youth (SUAY)  
 
Title: Safer Use of Antipsychotics in Youth (SUAY)  
 
NCT: [STUDY_ID_REMOVED]  
 
Dated: 7/18/[ADDRESS_870496] updated: 12/20/2019  
  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870497] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
  
 
Safer Use of Antipsychotics in Youth (SUAY)  
PHASE 3 – PRAGMATIC TRIAL  
 
Contract Number:  HHSN 271201600 0002  C 
 
Principal Investigator:  [INVESTIGATOR_286705], PhD  
Contracting Officer’s Representative : Adam Haim, PhD  
 
Version Number:  V5 
20 December 2019  
 

PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870498] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
1 
  
SIGNATURE [CONTACT_286732] s constitut ing approval of this protocol and the attachments, and provid ing necessary 
assurances that this trial will be conducted according to all stipulations of the protocol, including all 
statements regarding confidentiality, and according to local legal and regulatory requirements and 
applicable U .S. federal regulations and guidelines  are maintained electronically due to the multiple 
health systems and IRBs involved in this study Signatures can be found on the study’s private web 
portal.  
 
Signatories for this protocol are:  
Robert Penfold, PhD – Principal Investigator  
[INVESTIGATOR_649468], PhD – Site Investigator  
Director of Quality Improvement and Strategic Research  at the Institute for Health Research  
Kaiser Permanente Colorado   
 
Kelly Ke lleher, MD – Site Investigator  
Director  
The Research Institute at Nationwide Children’s Hospi[INVESTIGATOR_649469], PhD  – Site Investigator  
Distinguished Investigator, Associate Director, Science Programs  Kaiser Permanente Northwest  
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870499] Number:  HHSN [ADDRESS_870500] OF ABBREVIATIONS  ................................ ................................ ................................ .....................  5 
PROTOCOL SUMMARY – SUAY PRAGMATIC EFFECTIVENESS TRIAL  ................................ ......................  [ADDRESS_870501] INFORMATION  ................................ ................................ ..................  9 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ............................  10 
2.1 Background Information  ................................ ................................ ................................ ...... 10 
2.2 Rationale and Objectives  ................................ ................................ ................................ ..... 11 
3 OUTCOME MEASURES  ................................ ................................ ................................ .............  12 
3.1 Primary  ................................ ................................ ................................ ................................ . 12 
3.2 Secondary  ................................ ................................ ................................ .............................  12 
4 TRIAL DESIGN  ................................ ................................ ................................ .........................  13 
5 STUDY ENROLLMENT AND WITHDRAWAL  ................................ ................................ ................  14 
5.1 Prescribing Clinicians: Inclusion and Exclusion Criteria for Provider Subjects  .....................  14 
5.2 Patients and Families: Inclusion and Exclusion Criteria for Patient Subjects .......................  14 
5.3 Provider Randomization Assignment Procedures  ................................ ................................  15 
5.3.1  Randomization Procedures  ................................ ................................ .....................  15 
5.3.2  Blinding  ................................ ................................ ................................ ...................  16 
5.3.3  Cross -Over Prevention Procedures  ................................ ................................ .........  16 
5.4 Withdrawals  ................................ ................................ ................................ .........................  16 
5.5 Opting Out of Study Components  ................................ ................................ ........................  17 
6 CONTROL ARM  ................................ ................................ ................................ .......................  18 
7 INTERVENTION ARM  ................................ ................................ ................................ ...............  19 
7.1 Intervention Arm Medication Alert Intervention Description  ................................ .............  19 
7.2 Eligibility Confirmation  ................................ ................................ ................................ .........  19 
7.3 CAP Case Review and Consultation Intervention Description  ................................ .............  19 
7.3.1  Administration of CAP Case Review and Consultation  ................................ ...........  20 
7.3.2  Procedures for Training Study CAPs and Fidelity Monitoring  ................................ . 20 
7.4 Behavioral Health Navigation Description  ................................ ................................ ...........  20 
7.4.1  Administration of BH Navigation Intervention  ................................ .......................  21 
7.4.2  Procedures for Training of BH Navigators on Intervention  ................................ .... 22 
7.5 Short -Term Bridging Therapy Description  ................................ ................................ ...........  22 
7.5.1  Administration of Bridging Therapy  ................................ ................................ ........  22 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870502] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
3 
 7.5.2  Procedures for Training of Therapi[INVESTIGATOR_649470]  ................................ .. 23 
8 STATISTICAL CONSIDERATIONS ................................ ................................ ................................  24 
8.1 Sample Size Considerations  ................................ ................................ ................................ . 24 
8.2 Primary Analysis Plan  ................................ ................................ ................................ ...........  24 
8.2.1  Statistical Analysis Plan  ................................ ................................ ...........................  24 
8.3 Handling of Missing Data  ................................ ................................ ................................ ..... 27 
9 PRAGMATIC TRIAL OVERSIGHT  ................................ ................................ ................................  29 
9.1 Data Safety Monitoring  ................................ ................................ ................................ ........  29 
9.1.1  Schedule and Content of DSMB Reports  ................................ ................................  29 
9.2 Premature Termination or Suspension of Trial  ................................ ................................ .... 29 
10 ASSESSMENT O F SAFETY  ................................ ................................ ................................ .........  30 
10.1  Specification of Safety Parameters  ................................ ................................ ......................  30 
10.1.1  Safe Practice Protocols and Tracking  ................................ ................................ ...... 30 
10.1.2  Adverse Events (AE) / Serious Adverse Events (SAE) and Reporting  ......................  30 
10.1.3  Unanticipated Problems and Reporting  ................................ ................................ .. 31 
10.2  Halting Rules  ................................ ................................ ................................ ........................  31 
11 CLINICAL SITE MONITORING  ................................ ................................ ................................ .... 32 
12 QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ................................ ........  33 
12.1  Study Procedures  ................................ ................................ ................................ .................  33 
12.2  Quality Management  ................................ ................................ ................................ ...........  33 
12.3  Protocol Deviations  ................................ ................................ ................................ ..............  33 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................ ................................ .............  [ADDRESS_870503]  ................................ ................................ ................................ ... 34 
13.4  Informed Consent Process  ................................ ................................ ................................ ... 35 
13.5  Exclusion of Women, Minorities, and Children (Special Populations)  ................................ . [ADDRESS_870504] POLICIES  ................................ ................................ ...... 38 
16 DATA SHARING PLAN  ................................ ................................ ................................ ..............  39 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870505] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
4 
 17 LITERATURE  ................................ ................................ ................................ ............................  40 
PROTOCOL APPENDICES  ................................ ................................ ................................ ...................  43 
APPENDIX A: SCHEDULE OF EVENTS  ................................ ................................ ................................ .. 44 
APPENDIX B: PROVIDER ADVANCE COMMUNICATIONS AND MEDICATION ALERTS  ............................  46 
APPENDIX C: SUAY CLINICAL GUIDANCE  ................................ ................................ ...........................  47 
APPENDIX D: BH NAVIGATION  ................................ ................................ ................................ ..........  48 
APPENDIX E: TELEMENTAL HEALTH BRIDGING  ................................ ................................ ..................  49 
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870506] Number:  HHSN [ADDRESS_870507] OF ABBREVIATIONS  
ADHD  Attention Deficit Hyperactivity Disorder  
AE Adverse Event/Adverse Experience  
APA American Psychiatric Association  
BH Behavioral Health  
CAP Child and Adolescent Psychiatrist  
CD Conduct Disorder  
CFR Code of Federal Regulations  
DSMB  Data and Safety Monitoring Board  
EMR  Electronic Medical Record  
FDA Food and Drug Administration  
FTE Full Time Equivalent  
FTP Secure File Transfer Protocol  
HCSRN  Health Care Systems Research Network  
HIPAA  Health Information Portability and Accountability Act  
IRB Institutional Review Board  
KP Kaiser Permanente  
KPWA  KP Washington  
KPWHRI  KP Washington Health Research Institute  
MHRN  Mental Health Research Network, HCSRN  
NIMH  National Institute of Mental Health, NIH  
ODD  Oppositional Defiant Disorder  
OHRP  Office of Human Research Protections  
PAL Partnership Access Line  
QMP  Quality Management Plan  
SAE Serious Adverse Event/Serious Adverse Experience  
SUAY  Safer Use of Antipsychotics in Youth  
TMH  Telemental Health  
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870508] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
6 
 PROTOCOL SUMMARY  – SUAY PRAGMATIC EFFECTIVENESS TRIAL  
Title:  A Pragmatic Effectiveness Trial: Safer Use of Antipsychotics in Youth (SUAY)  
Précis: A pragmatic encouragement trial will test the effectiveness of an intervention 
aiming to improve the targeted and safer use of antipsychotic medications  by 
[CONTACT_649508] -prescribing behavior of antipsychotics for children aged ≥ 3 
and < [ADDRESS_870509] . 
The control arm medication alert will point p rescribing clinicians to relevant 
Choosing Wisely®  recommendations. The intervention arm medication alert will 
inform  prescribers  that: 
1. Antipsychotic s are not recommended 1st line treatment for non -
psychotic disorders ; 
2. A child and adolescent psychiatrist (CAP) will review antipsychotic 
usage by [CONTACT_91948] ;  
3. Expedited access to bridging  therapy , behavior health navigation, 
and/or a proactive consultation with a CAP may be ordered .  
The intervention medication alert will point prescribing clinicians to both 
Choosing Wisely®  recommendations and clinical guidelines  for SUAY .  
Analytic d ata will be collected from automated data sources at the health 
systems . The primary outcomes are percent of children taking  an antipsychotic 
medication at [ADDRESS_870510] udy period  – based on medication order 
data .  
Objectives:  Test the effectiveness of the intervention treatment algorithm vs. usual care 
control in a practical clinical trial involving  several hundred subjects in multiple 
health systems.  
Population s: Providers authorized to order prescri ption  medications in the health system’s 
electronic medical record .  
Patients aged ≥ 3 and <18 year s without diagnosed  psycho sis, mania, autism 
spectrum disorder , or intellectual disability .  
Number of Sites:  1. Kaiser Permanente Washington  
2. Kaiser Permanente Colorado  
3. Nationwide Children’s Hospi[INVESTIGATOR_307]  
4. Kaiser Permanente Northwest  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870511] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
7 
 Description of 
Intervention:  The intervention arm medication alert prompts the prescriber to (a) 
keep/remove the antipsychotic order , and/or (b) order behavioral health ( BH) 
navigation , and/ or (c) order expedited access to psychotherapy (e.g., 
telemental health bridging ) for the patient/f amily, and/or ( d) order a provider -
to-provider virtual consult with a child and adolescent psychiatrist (CAP).  
Case review by a child and adolescent psychiatrist will automatically occur for 
all eligible intervention arm patients . A provider -to-provider c onsult will be 
scheduled if either (a) the prescriber ordered the consult or (b) the CAP needs 
to discuss the case with the prescriber to complete his/her review.  
Following review by [CONTACT_244596], a BH navigator  messages the prescriber and 
reach es out to the eligible intervention arm patient/ family to offer extra 
support (unless actively declined by [CONTACT_649509]) . The navigator’s role 
is to (a) provide extra support to facilitate access and engagement in 
appropriate psychosocial therapi[INVESTIGATOR_014]; (b) coordinate short -duration  bridging 
therapy sessions for teens/families  not engaged in psychotherapy, when 
appropriate ; and (c) keep the prescriber info rmed of any clinically relevant 
updates.  
Trial Duration:  [ADDRESS_870512] 
Participation 
Duration:  Up to 30 months for clinicians  
6 months for patients  
Estimated Time to 
Complete 
Enrollment:  24 months  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870513] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
8 
 Schematic of Study Design:  
 
PHASE 3 PRAGMATIC EFFECTIVENESS TRIAL
Patient Encounter  
Outpatient antipsychotic 
medication entered in 
Epic
Intervention 
medication alert fires; 
patient added 
to study logControl medication 
alert fires; patient 
added to study log
Standard CareCase review by [CONTACT_649510] 
(CAP)
6 months of BH Navigation offered
Analytic data data collected for 6 month follow up periodProvider pre -randomization and advanced study notification 
CONTROL INTERVENTION
Patient Encounter  
Outpatient antipsychotic 
medication entered in 
Epic
 Eligibility 
confirmedExcluded
EligibleEligibility 
confirmedIneligible
CAP recommendations 
shared with prescriber 
and study navigatorIneligible
Extra support to access and stay 
engaged in BH careTMH Bridging
Transition to BH Caredeclined
acceptedPatient added 
to study logPatient Encounter  
BHN, bridging, or CAP 
consult ordered directly in 
Epic (i.e., outside the 
medication alert)Either
AP or CAP 
consult 
ordered?Eligible
Yes
No
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870514] Number:  HHSN [ADDRESS_870515] INFORMATION  
Principal Investigator :   [INVESTIGATOR_286705], PhD , Scientific Investigator  II 
Kaiser Permanente Washington Health Research Institute  (KPWHRI)  
[ADDRESS_870516]  
Seattle, WA [ZIP_CODE]  
[EMAIL_5608]  
(206) 287 -2232  
Program Official:    Adam Haim , PhD  
Site Investigator s: Arne Beck, PhD, Kaiser Permanente Colorado  
Kelly Kelleher, MD , Nationwide Children’s Hospi[INVESTIGATOR_649471]:  Kaiser Permanente Washington   
Nationwide Children’s Hospi[INVESTIGATOR_649472]’s Hospi[INVESTIGATOR_649473]-Investigators : Robert Hilt, MD , Seattle Children’s Hospi[INVESTIGATOR_649474], MD, Seattle Children’s Hospi[INVESTIGATOR_649475], MD, MPH , KPWHRI  
Rebecca Yates Coley, PhD , KPWHRI  
James Ralston, MD, MPH , KPWHRI  
Arne Beck, PhD, Kaiser Permanente Colorado  
Kelly Kelleher, MD , Nationwide Children’s Hospi[INVESTIGATOR_649476], PhD , Kaiser Permanente Northwest  
Paul Fishman, PhD , University of Washington  
Consultants:  Katherine (Katie) Odem -Davis, PhD , University of Washington  
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870517] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
10 
 2 INTRODUCTION : BACKGROUND INFORMATION  AND SCIENTIFIC RATIONALE   
2.1 Background Information  
Beginning in the mid 1990’s, rates of prescribing antipsychotic medications to children and adolescents 
grew tremendously (1-6) and remain high in both Medicaid and commercially insured populations (6-9). 
Most antipsychotic medications prescribed to children are “second generation” or “atypi[INVESTIGATOR_2855]” 
antipsychotic medications. We will refer to these simply as antipsychotics. These medications are argued 
to have milder side effect profiles (e.g., reduced extra pyramidal symptoms) than older “first generation” 
or “typi[INVESTIGATOR_2855]” antipsychotic medications. However, the side effects of newer APs can still be severe (10, 
11). The side effect profiles of individual medications in the same class differ significantly and their 
impact on the individual patients who take them are also known to differ (12-14).  
The vast majority of antipsychotic  use in youth aged 5 -17 years is for non -psychotic disorders and is 
particularly prevalent in youth with a diagnosis of attention deficit hyperactivity disorder (ADHD) with 
comorbid conduct disorder (CD) or oppositional defiant disorder (ODD) and/or impulsive aggression (7, 
15, 16) . For example, we analyzed a sample of 562,423 youth prescribed psychotropic medications in 
our Mental Health Research Network (MHRN) , a consortium of [ADDRESS_870518] one prescription for an antipsychotic medication, during the year 
2011 alone. In this sample, 66% of boys aged [ADDRESS_870519] a psychotic disorder or other FDA -
approved indication. (See Penfold et. al ., 2013 for a detailed breakdown of antipsychotic medication use 
in MHRN.)  
In its Choosing Wisely ® recommendations, the American Psychiatric Association lists as its 5th 
recommendation: Don’t routinely prescribe an antipsychotic medication to treat behavioral and 
emotional symptoms of childhood mental disorders in the absence of approved or evidence su pported 
indications (17). However, not all antipsychotic prescribing for emotional and behavioral disturbances is 
inappropriate. It may be reasonable for clinicians to prescribe antipsychotics when youth are a danger to 
themselves or others and/or not responding to prim ary treatments in the absence of a psychotic 
disorder. Nevertheless, a new and updated algorithm and workflow is needed to guide clinicians 
regarding when and how to prescribe antipsychotic medications to youth with non -psychotic disorders. 
Importantly, th ere are a number of reasonable algorithms for antipsychotic prescribing to youth (18-23); 
however, there are two fundamental gaps in our understanding of how to implement such guidelines:  
(a) how to support clinicians most effectively in following the algorithms and ( b) how to increase access 
to psychosocial primary treatments that all of the existing guidelines recommend as part of first line 
treatment (in addition to non -antipsychotic me dications). A new algorithm will be largely ignored unless 
we address the fundamental issues of implementation (24-31) and long known barriers to changing 
prescribing practices addressed in the academic detailing literature (32-39). 
In phase 1 of SUAY, a sequenced treatment algorithm and clinical workflow were developed. The  study 
is inspi[INVESTIGATOR_649477] (PAL) and Second Opi[INVESTIGATOR_649478]. Implementa tion of this program in Washington resulted in 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870520] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
11 
 a 50% reduction in antipsychotic medication use among Medicaid insured youth over its first four years. 
Second Opi[INVESTIGATOR_649479] a 51% decrease in outlier ADHD stimulant 
medication pres cribing, coupled with a 10:1 return on investment (40). Similar peer consult programs 
have been demonstrated effective in other settings. (41, 42)  In its cur rent form, this program requires an 
outpatient pharmacist to hold a prescription awaiting Medicaid authorization for an antipsychotic 
outside of an established state guideline until there is documentation of a consult between the 
prescribing provider and a  child and adolescent psychiatrist (CAP) at Seattle Children’s Hospi[INVESTIGATOR_307]. 
Providers can also electively reach out to the team’s consultants via the PAL service line to discuss best 
practice care in a state -wide rapid access program staffed by 1.[ADDRESS_870521] being considered and 
discussed. The core elements of our proposed interv ention are: ( a) sequenced ‘treatment alternatives ’ 
algorithm based on best evidence that accommodates diversity of practice; ( b) effective clinical decision 
support (including human consultation) integrated into the flow of practice; ( c) behavioral health 
navigation  for psychosocial treatment alternatives that are effective and acceptable to families; and ( d) 
expedited access to evidence -based psychosocial therap y. 
 
2.2 Rationale  and Objectives  
Antipsychotics are prescribed to children for a number of behavioral health conditions despi[INVESTIGATOR_649480]. Such ‘off label’ use of antipsychotics exposes 
children to significant health risks. The SUAY trial aims to minimize use of antipsychotics to treat non -
psychotic behavioral disturbances in children in four real -world health care systems.  
The pragmatic encouragement trial will assess the effectiveness of an intervention aiming to improve 
patient safety by [CONTACT_649511] ≥ 3 and < [ADDRESS_870522] and extra patient -facing support to improve be havioral health service access  
(e.g., navigation, TMH) .  
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870523] Number:  HHSN [ADDRESS_870524] 
deliverable : 
• Percent of youth using antipsychotics at 6 months , measured by  [CONTACT_649512] 180 day follow up period ; 
• Total person -months of antipsychotic use by [CONTACT_91948] , measured by  [CONTACT_649512] 180 day follow up period.  
3.2 Secondary  
The following secondary quantitative outcome measures for the trial will be assessed:  
• Percent of youth using antipsychotics at 6 months , measured by  [CONTACT_649513] 180 day follow up period;  
• Total person -months of antipsychotic use by [CONTACT_91948] , per prescription fill data available for the 
180 day follow up period.  
• Emergency department /urgent care  visit frequency , both  for psychiatric crises  and for other 
reasons ; 
• Percentage of baseline and follow -up safety assessments (i.e., BMI measurement and laboratory 
results) ;  
• Percentage of c linician s that follow CAP advice according to  algorithm ;  
• Modal stage at departure  from algorithm (first line, second line, third line treatment prior to 
antipsychotic) ; 
• Percentage  of patients with change to psychotropic medication treatment plan following second 
opi[INVESTIGATOR_649481] ; 
• Percent of patients that agree to behavioral health ( BH) navigation ; 
• Percentage of patients attending two or more system -provided therapy  sessions ; 
• Percent age of patients attend ing two or more study -provided  therap y sessions ; 
• Of patients in study therapy, p ercent age who subsequently  attend two or more system -
provided therapy sessions . 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870525] Number:  HHSN [ADDRESS_870526] a two -group pragmatic encouragement clinical trial comparing the intervention and 
control at multiple sites . The follow up period  for the trial will be 6 months.   
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870527] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
14 
 5 STUDY ENROLLMENT AND WITHDRAWAL  
5.1 Prescribing Clinicians : Inclusion and Exclusion Criteria  for Provider Subjects  
A site programmer will randomly assign providers  to one of two study arms  prior to fielding . 
Randomization determines which study medication alert the  provider will  receive . Intervention arm 
providers have the a bility to  order  extra support  from the study : 
• A provider -to-provider consult with a child and adolescent psychiatrist (CAP), and/or ; 
• Behavioral health navigation  for the patient/family , and/or ; 
• Expedited access to psycho therapy (e.g., telemental  health)  for the patient/family . 
All randomized providers will receive advance notification of the study launch . Providers in the 
intervention  arm will be told about the extra support that may be ordered and given a web -link to the 
expert clinical guidelin es developed for SUAY . The control arm provider s will be informed that a research 
study is being conducted to improve the quality of antipsychotic medication prescribing.  
Inclusions :  
• Clinician is c redentialed to order prescription medications  in the health system’s electronic 
medical record ( EMR ). 
Exclusions :  
• Clinician p ractices outside of the delivery system (e.g., external or network provider) . 
5.2 Patients and Families : Inclusion and Exclusion Criteria  for Patient Subjects  
Potentially eligible  patients are logged for study enrollment at the time the medication alert fires . 
Patients are assigned to the study arm of the randomized prescribing provider. Local study staff will 
blindly confirm eligibility via medical record review for all intervention and control arm patients logged  
for eligibility review and enrollment .  
Inclusions:  
• Patient is ≥ 3 and < 18 years of age at the time of the encounter  at which the study alert fired ;  
• Study service (BH navigation, bridging therapy , CAP consult) ordered in Epic for the patient ;  
o The BPA allows providers to remove the antipsychotic order and still order services . 
• Patient is initiating a new epi[INVESTIGATOR_649482].  
o New epi[INVESTIGATOR_649483] 180 days.  
Exclusions :  
• Patient has a diagnosed psychotic disorder, mania, autism spectrum disorder, or intellectual 
disability ; 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870528] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
15 
 • Patient was enrolled in the SUAY pi[INVESTIGATOR_799] ; 
• The antipsychotic entered is prochlorperazine (Comazol®)  – which is used to treat nausea;  
• An o utpatient antipsychotic order  is entered by a temporary provid er in the health 
system.  For example, a “doc of the day” signing an order initiated by a pharmacist 
transferring an existing prescription to the health system . This situation may also occur 
when a temporary provider signs a medication order for a prescript ion initiated in an 
inpatient setting  as part of a discharge plan . 
o Note that orders placed by [CONTACT_649514] 180 
day medication free period for defining a new epi[INVESTIGATOR_9694].  
• The a ntipsychotic order was placed  with in an urgent  care, emergen cy department, or  inpatient  
setting (to avoid intervening during a crisis) .  
o Note that orders placed in these settings do not count towards the 180 day 
medication free period for defining a new epi[INVESTIGATOR_9694].  
• Primary language is not English  (e.g., patient requires a translator) . 
5.[ADDRESS_870529] prescribing behavior may vary 
across study sites based on available provider data but will gener ally include the absolute number of 
qualifying prescriptions as well as the rate of qualifying prescriptions (per number of visits billed or 
number of unique patients seen, as available). Providers in certain departments may also be more likely 
to write qu alifying prescriptions. For example, providers who specialize in mental or behavioral health or 
providers in clinics focusing on higher risk adolescents. The particular departments associated with more 
qualifying prescriptions will be identified separately  for each health system based on previous 
prescribing patterns and knowledge of that health system.  
Providers in each health system will divided into as few as two randomization blocks (likely and unlikely 
prescribers) and as many as four randomization bl ocks (unlikely, likely, high frequency, and very high 
frequency) based on the total number and distribution of expected number of qualifying prescriptions. 
For example, KP Washington providers wrote fewer than 100 qualifying prescriptions in the yearlong 
interval examined and the distribution of qualifying prescriptions per provider had a long right tail 
indicating that a small number of physicians wrote a large number of quali fying prescriptions. In this 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870530] Number:  HHSN [ADDRESS_870531] eligibility .  
The detail s of the study design will not be known by [CONTACT_649515]  (i.e., outcome assessments will be blinded).  
Study child and adolescent psychiatrists, behavioral health navigators, and therapi[INVESTIGATOR_649484]. G roup assignment is therefore known to these study staff.  
The PI [INVESTIGATOR_649485] -up is complete . 
Only data coordinating center staff will be un -blinded to arm when preparing harm reports for the 
DSMB) . Investigator s will be un -blinded for report ing any intervention arm incidental death s to the 
NIMH DSMB, should such events occur during the course of the trial . 
5.3.[ADDRESS_870532] as planned.  
If a control  arm provider reaches out for a consult ation , the CAP may still discuss treatment options and 
make recommendations as they would as part of their normal role . 
The behavioral health navigator  will be responsible for ensuring that the services s/he offers and the 
bridging therapy are only access ible to intervention  arm patients and providers.   
Patients who change to the panel of a provider assigned to a different arm during the [ADDRESS_870533] ( IRB) at each site. Neither 
providers nor patient -subjects may withdraw given the pragmatic design and intent -to-treat  analysis  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870534] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
17 
 plan . Subjects remain in the study regardless of their acceptability or degree of exposure to 
interventional components, given the encouragement trial design.  
5.5 Opting Out of Study Components  
Medication  alert : Providers may cancel the medication alert by [CONTACT_649516] -selecting the antipsychotic in 
Epic and not ordering any extra support (i.e., CAP consultation , BH navigation, expedited psychotherapy 
access ).  
CAP review : Intervention arm p rescribers may not opt out of passive CAP review s. Control arm 
prescriber s are not included in CAP review.  
• The CAP is automatically informed of the need for a passive review  (i.e., provider did not order a 
consult) after eligibility is confirmed .  
• The CAP is automatically informed of the need for an active review (i.e., provider ordered a 
consult), prior to eligibility confirmation  to avoid any delay.  
o If the patient is deemed ineligible upon review, other study services will not be offered 
to the patient/family.  
• Passive CAP review will still occur if the clinician click ed an exclusion in the BPA (e.g., autism)  
and the patients is subsequently verified to be eligible . That is, study staff (not the prescriber) 
determines study eligibility.   The prescriber maintains his/her clinical autonomy and may opt not 
to follow the CA P’s treatment recommendations . No treatments or medications are withheld at 
any time.   
CAP consultation : The study CAP may still reach out to an intervention arm prescriber to discuss a case 
when a CAP consult was not ordered. The prescriber  may decide not to respond t o or schedule with the 
CAP. The prescriber maintains his/her clinical autonomy and may opt not to follow the CAP’s treatment 
recommendations . No treatments or medications are withheld at any time.  Secondary outcomes 
include: the percentage  of clinicians that follow CAP advice; the percentage of patients with a change to 
psychotropic medication treatment plan  following CAP review; and model stage of departure from the 
algorithm (first line, second line, third line treatments prior to antipsy chotic).  
Behavioral health navigation : Intervention  arm p roviders may decline behavioral health navigation for 
their patient  by [CONTACT_20230] a staff message from the navigator . Families /teens  contact[CONTACT_649517].  Secondary outcome s include the 
percentage of patients that agree to behavioral health navigation, and the percent of patient that attend 
2 or more face -to-face therapy sessions . 
Expedited access to bridging  therap y: Intervention arm providers may decline bridging therapy for the 
patient/family by [CONTACT_20230] a staff message from the navigator. Families/teens offered study 
bridging therapy may decline it at any time.  The percent of patients that attend two of more bridging 
sessions with a study therapi[INVESTIGATOR_649486] a secondary outcome of the study.  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870535] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
18 
 6 CONTROL  ARM  
The control  arm advance communication and medication alert inform  the prescriber of Choosing 
Wisely®  recommendations r egarding antipsychotic medications in children and adolescents. These 
guidelines were developed by [CONTACT_216418] (APA). Available at: 
http://www.choosingwisely.org/clinician -lists/american -psychiatric -association -antipsychotics -in-
children -or-adolescents/  
The firing of the control arm medication alert will add the patient to the study enrollment log as a 
comparison case. Study staff will confirm eligibility via blinded chart review for all patients logged.  
The follow up period is 6 months.  
Should a control arm  provider find SUAY orders in Epic and atte mpt to order a study service (e.g., 
navigation, expedited access to bridging  therapy ), an alert will fire to inform  him/her that the patient is 
not eligible for the service.  
 
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870536] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
19 
 7 INTERVENTION ARM  
7.1 Intervention Arm Medication Alert Intervention Description  
Randomized p roviders at each site will be informed in advance of the quality improvement study  being 
conducted . The communication will inform intervention arm providers of the nature of the 
interventional components (e.g., medication alert, case review by a child and adolescent psychiatrist, 
behavioral health navigation, bridging  therapy ). 
The medication alert is triggered by [CONTACT_649518] a target patient . See Appendix 
B. The patient is added to a study enrollment log at the time of the encounter . The intervention  arm 
medication alert links providers to a document containing Choosing Wisely®  guidelines , the national 
expert consensus panel clinical guidelines developed for SUAY , and contextual study  inform ation .  
Within the alert, t he p rescriber has the option to:  
• keep /remove  the medication entered (default = remove)  
• keep/remove an order for a provider -to-provider consult with the CAP (default = keep)  
• keep/remove an order for  BH navigation for the patient ( default = keep)  
• keep/remove an order for  expedited access to bridging therapy for the patient (default = keep)  
The study CAP is automatically notified  that a review is needed  each time an intervention arm provider 
actively orders a CAP review in the alert and after a patient is verified eligible when a consult is not 
actively ordered.  
7.2 Eligibility Confirmation  
Study staff (PI [INVESTIGATOR_9232]) blinded to arm assignment will conduct a focused medical record review 
within [ADDRESS_870537] of study inclusion and exclusion criteria for this review.  
Patients found not to meet criteria will be flagg ed as ineligible and the reason(s) noted in the study log. 
Patients found to meet all study criteria will be flagged as eligible. Upon being thus flagged, eligible 
intervention subjects will be ‘released’ to the CAP and navigator.  
7.[ADDRESS_870538]. See Appendix C. This will guide the CAP as s/he reviews the clinical scenario around each 
antipsychoti c order (e.g., treatment history, current treatments, diagnoses) to determine the next best 
step in the treatment plan. If information is missing or the prescription is not in line with expert clinical 
guidance, the CAP may attempt to contact [CONTACT_649519] r to discuss the appropriateness of proceeding 
to an antipsychotic for the case and possible revisions to the treatment plan. The CAP will provide the 
prescriber with a written recommendations summary for every review completed. A standardized 
template wil l be used. The CAP’s recommendations may be noted in the medical record.  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870539] Number:  HHSN [ADDRESS_870540] the CAP’s recommendations. There are no negative 
consequences to providers if CAP treatment recommendations are not implemented. That is , the 
prescriber’s clinical autonomy is in no way constrained or diminished.   
7.3.1 Administration of CAP Case Review and Consultation  
Case review  of intervention arm patients  will be conducted by a study CAP within 3 business days of 
receiving notification of the case at each site . If a provider -to-provider discussion is deemed necessary 
by [CONTACT_649520] a consult directly, a virtual consult  between the CAP and 
prescriber will be arranged within 2 weeks of  the visit.  
The CAP’s review outcomes will be sent to the prescriber and may be noted in the patient’s chart . The 
exact procedure will vary by [CONTACT_3725]. T he CAP s may also provide guidance to the navigator (e.g., patient is 
not a good candidate for telemental h ealth , etc.)  
Filling of the script is not delayed by [CONTACT_649521]. However, existing Washington 
State law requires antipsychotic scripts for children on Medicaid to be held at the pharmacy until pre -
authorization  is granted by [CONTACT_382021]. This process is outside the control of the project  at KPWA .  
CAP recommendations : A structured template will be used by [CONTACT_649522]. Feedback will be shared with the prescriber for every case 
reviewed. This includes  situations where the CAP agrees with the antipsychotic order and/or if the CAP 
discussed the case with prescriber directly (e.g., by [CONTACT_648], email, or in person ).  
7.3.[ADDRESS_870541]. Robert Hilt of Seattle Children’s Hospi[INVESTIGATOR_649487]. He will train study CAPs at other clinical 
sites , as needed , on the study protocol, SUAY guidelines, and CAP consultation best practices .  
Site CAPs will meet by [CONTACT_649523].  Recommendations will be periodically quality check ed in Epic to 
ensure CAPs are adhering to and completing the structured recommendations template for the study.  
7.[ADDRESS_870542] review within 3 business days of the patient being add ed 
to the study enrollment log at each site.  
Initial provider outreach : The behavioral health navigator will contact [CONTACT_649524] 2 business days of the CAP providing his/her summary of review outcomes . When a 
provider actively ordered a study service for their patient, the navigator wil l send the provider a short 
message. When a study service was not explicitly ordered  for an eligible patient , the navigator will 
introduce him/herself to the provider in a staff message, briefly describe the extra support the BH 
navigation can offer the patient , and inform the provider that s/he may respond by [CONTACT_649525], if desired.  If a provider contacts a navigator directly 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870543] Number:  HHSN [ADDRESS_870544] the teen/family to offer behavioral health navigation.  
Initial patient outreach : Waivers of consent/ass ent are obtained from the reviewing IRBs. BH navigator s 
at each site will administer the equivalent of modified oral consent /assent  by [CONTACT_648] , as required by [CONTACT_36349], when calling to offer up to [ADDRESS_870545].  
Follow up patient outreach : If the teen/family agree  to BH navigation, the navigator will initiate contact 
[CONTACT_649526] 6 month follow up period to inquire about the child’s status and re -evaluate 
barriers to access. The navigator will use motivational interviewing techniques (e.g., reflective listening, 
asking open ended questions) with the youth and/or parents to encourage them to engage in 
psychosocial treatments , attempt to motivate them to continue or restart therapy (as needed), and 
identify and help problem -solve ways to minimize barriers to starting or continuing therapy . When 
barriers exist, s /he will offer assistance in identifying behavioral health clinicians  that may be a good fit 
for the family/teen , and further assess appropriateness of short -term bridging  therapy .  
The navigator will remind teens/families, as appropriate, that laboratory tests are due to be completed 
[ADDRESS_870546] information incidentally reported by [CONTACT_9166]/family 
in the phone note. If a reported side effect is burdensome, the navigator will encourage the patient or 
parent/guardian to contact [CONTACT_649527].  
The navigator will follow the study Safe Practice Protocol if suicidal ideation is incidentally revealed  by a 
subject during a BH navigation outreach call.  
Ad hoc patient outreach : The navigator will reach out to assess barriers and attempt to motivate the 
teen/family to continue therapy if a BH appointment is missed and not rescheduled within 2 weeks.  
Final patient outreach call : The navigator will conclude services with a review of the agreed upon plan 
for next steps and encouraging continued contact [CONTACT_649528] . 
Follow up provid er outreach : Following each outreach call, the navigator will secure message the 
prescriber with relevant updates, as needed.   
 
7.4.1 Administration of BH Navigation  Intervention  
An Epic  reporting workbench will be used to support BH navigation at each site . Navigators will be 
prompted to follow up with subjects at the appropriate time points , log outreach atte mpts and 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870547] Number:  HHSN [ADDRESS_870548] s’ acceptance  or refusal of navigation and (if offered) short term bridging  
therapy , and track subject adherence to the treatment algorithm.  
7.4.[ADDRESS_870549] based on 
the clinical scenario.  The BH navigator will use a decision tree to further assess appropriateness of short -
term bridging therapy . Any r eason that bridging is not offered will be n oted in the navigator ’s reporting 
workbench (e.g., declined by [CONTACT_649529],  CAP advised against , subject already engaged in therapy , etc. ).  
The BH navigator will administer modified oral consent/assent for bridging services, as required by [CONTACT_36349], schedule the initial session,  and note if the teen/family requires a loaner device  (e.g., tablet ) if 
bridging visits are to be delivered via telemental health ( TMH ) video visits . 
When TMH is to be delivered, a TMH privacy and safety plan with the subject prior to the first TMH 
session . The offer of TMH will be suspended if a privacy or safety concern is identified when the form is 
completed until a clinical decision can be made by [CONTACT_38802][INVESTIGATOR_541]. The plan identifies resources within and 
outside the home to ensure patient privacy during TMH sessions, and plan for any potential crises, 
safety concerns, or inability to contact [CONTACT_9166]/family.  
All bridging visits will be entered in Epic as patient visits . There will be no copays or other charges billed 
for these study -related visits.  
7.5.1 Administration of Bridging Therapy  
Each health system  will identif y 1 or more licensed and credentialed therapi[INVESTIGATOR_649488] . Study sites will offer clinic -to-home telemental health (TMH) with a study therapi[INVESTIGATOR_649489] -
compliant video visit technology  when appropriate for and agreeable to the participant . Phone -based or 
in-person visits may be offered by [CONTACT_649530]/family preference  prohibit 
video -teleconferencing  visits . If a televideo connection cannot be established, the therapi[INVESTIGATOR_649490] (or complete) a TMH session without video.  
Appointments and set up  for TMH : Study staff will provide subjects with instructions  for joining 
telemental health sessions , as appropriate . Appointment reminders will be sent . Appointment 
reminders for TMH sessions  will include a link for the patient to join the next TMH session.  
If a s uitable personal device is not available  for video -visits , study staff will provide an inexpensive, 
secure loaner device to the subject  during their first appointment .  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870550] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
23 
 Content : The therapeutic content of bridging sessions is solely determined by [CONTACT_38802][INVESTIGATOR_649491] 1 and established, 
empi[INVESTIGATOR_412648] . The study is investigating methods to improve access  and use of 
psycho therapy;  not evaluating any specific psycho therapeutic interventions.  
Duration  and transition : Bridging will conclude after [ADDRESS_870551]. The extra support provided by [CONTACT_649531][INVESTIGATOR_467433]/family transition from bridging to ongoing psychosocial therapy  when appropriate .  
7.5.2 Procedures for Training of Therapi[INVESTIGATOR_649492], MD , MPH  of Seattle Ch ildren’s Hospi[INVESTIGATOR_649493] . She will meet by [CONTACT_649532][INVESTIGATOR_649494] . Protected health information (PHI) will not be shared.  
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870552] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
24 
 8 STATISTICAL  CONSIDERATIONS  
8.1 Sample Size Considerations  
We anticipate enrolling as many as 800 eligible patients  in the trial (up to 400 per arm) , with up to 360  
eligible patients in each arm remaining enrolled at 6 months of follow -up (i.e., 10% lost to follow -up).  
 
8.[ADDRESS_870553] tracking systems , the Epic EMR , and other health system data 
systems  for analysis. Sites will securely transfer limited dataset s to the data coordinating center at 
KPWHRI  at defined intervals .  
Data validation and quality assurance checks will be undertaken to ensure data collection during the 
study is sufficiently reliabl e.  
We will use descriptive statistics to summarize  adherence to the study algorithm . Specifically, we will 
summarize the patient characteristics (age, gender, race and ethnicity , diagnoses ) of those individuals 
enrolled in the study and we will summarize clinician adherence to the algorithm protocol  by [CONTACT_649533] . Modal stage at deviation from the protocol will be evaluated among clinicians deviating from 
the protocol; additionally,  modal algorithm stage of drop out among patients in the intervention  arm 
who receive antipsychotic treatment during the [ADDRESS_870554] 
enrollment and total person -months of ant ipsychotic use by [CONTACT_91948], based on prescription fill data.  
We will also measure: the percentage of patients with a change to psychotropic medication treatment 
plan following second opi[INVESTIGATOR_649481]; percent of patients that agree to BH navigation; percent of  
patients that attend 2 or more bridging therapy sessions; and percent of patients that attend [ADDRESS_870555] care .  
In order to capture any negative unintended consequenc es, we will compare the number of emergency 
department visits , successful and unsuccessful suicide attempts,  deaths, and hospi[INVESTIGATOR_649495] s over the 6 months following the intervention.  
8.2.1 Statistical Analysis  Plan  
All primary analyses will follow an intent -to-treat approach, including all individuals assigned to an 
intervention arm regardless of the amount of intervention received. Non -inferiority evaluations will also 
be evaluated in a supplementary “as treated” ana lysis, comparing outcomes according to treatments 
actually received by [CONTACT_649534] -up. This supplemental comparison is 
useful in a non -inferiority assessment due to the fact that the alternative hypothesis of “no effect”  is 
more likely in the presence of protocol violations and therefore the intent to treat approach will be anti -
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870556] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
25 
 conservative if many patients in the intervention arm , for example , revert to control. Also, non -
inferiority of Emergency Department visit rate i n the intervention arm compared to usual care  control 
will only be assessed on final analysis if superiority is shown for the primary endpoint of no antipsychotic 
use at 6 months.  
We will use Poisson regression to estimate (1) the percent of individuals using antipsychotics at [ADDRESS_870557] enrollment and (2) the total number of person -months of ant ipsychotic use by [CONTACT_649535] -up period , per provider medication orders,  in each of the study arms. We will use 
generalized estimating equations (43) to estimate the parameters in the Poisson regression model. We 
will use the robust sandwich estimator to ensure correct standar d errors for the intervention effect due 
to possible violation of the Poisson variance assumption (44); additionally, this will allow us to accoun t 
for any clustering within clinics (43) and providers. Poisson regression allows comparison of relative 
incident rates among the intervention arms when outcomes are not rare (45). Additionally, Poisson 
regression will allow us to control for pre -specified baseline covariates (age, gender, and race) as well as 
site differences in any antipsychotic use and allow for straightforward estimation of site -specific 
intervention effects in sensitivity analyses. For a secondary analysis, we will repeat this approach 
defining antipsychotic use with prescription fill data rather than order s.  
Data for our primary outcome of interest, any antipsychotic use, will be collected from electronic health 
records  on provider orders . Electronic health record data on prescription fills will be used to assess the 
secondary outcome (antipsychotic medica tion fills). This means that traditional study drop -out due to 
premature participant withdrawal from the study will not lead to missing data in primary analyses. 
However, there will be the potential for differential follow -up rates among individuals due to  youth 
disenrolling from their or their parent/guardian’s health plan. Death is also a possibility , but unlikely. We 
will compare those youth for whom we are only able to collect outcome information for a portion of the 
[ADDRESS_870558] complete 6 month follow -up 
information on their demographics, treatment group, and other salient baseline variables. We will 
account for differential follow -up times due to disenrollment in the Poisson regression model using an 
offset (46). Because our power calculations are based on excluding all individuals lost -to-follow -up due 
disenrollment, these estimate s are conservative.  
The secondary outcome of emergency department visits will be estimated by [CONTACT_649536], again using generalized estimating equations for the reasons listed above for the primary 
outcome. The intervention will b e compared for non -inferiority to control using a margin of M=1.5 . This 
margin of 1.5 for the rate ratio represents a threshold for the relative increase of 50%, beyond which we 
would consider unacceptable. Sikirica (2014) observed an annual rate of 0.39 p er year among 
adolescents with attention deficit/hyperactivity disorder who were taking antipsychotics (47). Using a n 
estimated rate of emergency department visits of 0.0325 per month on control (47), the non -inferiority 
margin of 1.[ADDRESS_870559] ( emergency department rate on algorithm 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870560] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
26 
 divided by [CONTACT_649537], estimated by [CONTACT_70246]) and 95% two -sided confidence interval 
(CI) will be compared to the non -inferiority margin (overall: M = 1.5) and non -inferiority of the algorithm 
approach will be declared if the entire coverage of the 95% CI is less than 1.5.  
In safety review reports, the ratio between arms of emergency department visit rates will be 
accompanied by a confidence interval and by [CONTACT_11339] -inferiority margin, 1.5, for reference.  Confidence 
intervals will be defined by [CONTACT_649538] 5,000 bootstrap samples. Resampling will be 
done on the cluster (provider) level and stratified by [CONTACT_649539]. 
Quantile -based confidence intervals will be identified using the appropriate percentil e corresponding to 
the Pocock alpha -spending function for interim analyses. Excess harm is observed if the entire coverage 
of the confidence interval for the rate ratio comparing the greater to the lesser rate of emergency 
department and urgent care visits  is greater than 1.5 . (While the final non -inferiority analysis for this 
safety outcome will use the robust sandwich estimator to ensure correct standard errors, the properties 
of this estimator are based on asymptotic behavior and small sample size perfor mance may be poor.)  
We anticipate initial follow -up of 800 patients, randomized to the two arms, with  720 patients 
remaining enrolled in the study at 6 months of follow -up (i.e., 10% lost to follow -up). Assuming a P<0.05 
alpha level, and based on an antici pated 95% of patients in the control arm using antipsychotics at 6 
months, this sample will ensure over 9 5% power to detect a 6% reduction in the percent of participants 
with any order for antipsychotic  medication s at [ADDRESS_870561] to ha ve 80% power 
to detect a 1 3% reduction in subgroups with exposures occurring with 25% prevalence, and 80% power 
to detect a 1 7% reduction in subgroups with exposures occurring with 18% prevalence (e.g., 
racial/ethnic minorities). A minimal clinically important difference of 10% was pre -specified to allow for 
evaluation of clinical significance as well as statistical significance  as well as statistical significance. We 
have over 90% power to detect a 10% reduction in antipsychotic use at 6 mo nths for patients in the 
intervention arm given a rate of 85%, 90%, or 95% use in the  control arm.   
As these power calculations are based on the assumed percent of pa rticipants on any antipsychotic  in 
the control arm and assumed pattern of intervention eff ects, we provide examples of detectable 
intervention effects corresponding to alternative scenarios  in the table that follows , including varying 
rates of subgroup prevalence to evaluate power regarding  intervention effectiveness in less prevalent 
minorit y groups . In summary, at a range of percentages of participants with any antipsychotic use in the 
control arm, we will have excellent power to detect a variety of  clinically meaningful intervention eff ects 
within the expected range.  
Using an estimated rate o f emergency department visits of 0.0325 per month on control (47) and with a 
one-sided 0.025 alpha level with equal allocation between groups, we estimate 71% power (48) with 400 
patients per arm and 67% power with 360 patients per arm (allowing for loss to follow -up) respectively, 
to detect equality of emergency departmen t visit rates (i.e., a true rate ratio of 1) in a non -inferiority 
evaluation with a margin of 1.5. With a greater monthly emergency department rate of 0.05, we would 
have 88% and 84 % power  with 400 and 360 patients per arm respectively  under otherwise equi valent 
conditions.   
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870562] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
27 
 Power under varying percent ages  of participants in each  arm taking  antipsychotic  medication  at 6 
months (based on medication orders) and under various subgroup prevalence assumptions . 
 
Subgroup 
prevalence  n per 
arm*  Intervention  Control  Power  
100%  360 89% 95% 80% 
100%  360 85%  95%  >99%  
100%  360 80% 90% 97% 
100%  360 75%  85%  92%  
25%  90 82%  95%  80%  
18%  65 78%  95%  80%  
10%  36 75%  95%  67% 
5% 18 65%  95%  62% 
 
 
8.[ADDRESS_870563] estimates. Our primary analyses will use an offset term (46) in the 
Poisson regression models in order to include all individuals regardless of the length of follow -up. We 
have performed conservative power calculations assuming that all individuals without a full 6 months of 
follow -up will be excluded from analyses. If disenrollment rate is high than anticipat e or there is missing 
information in important baseline characteristics we will use multiple imputation (49) or weighte d(50) 
estimates to ensure that our results are not biased due to missing data.  
One study site ( NCH) does not have complete prescription fill data  because they serve patients in their 
clinics who are not enrolled in the insurance product for  their health plan. Complete capture of 
prescription fill data does not differ  with study arm assignment, thus, we do not expect estimates of the 
interventions effect to be biased.  However, missing prescription fill data could lead to underestimates 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870564] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
28 
 of the percentage of yout h taking antipsychotics at 6 months and/or the percentage of youth who fill 
prescriptions for lower risk, first line medications. We will conduct quality assurance checks comparing 
the number of medication orders and prescription fills by [CONTACT_649540].  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870565] Number:  HHSN [ADDRESS_870566] (DSMB) will provide ongoing oversight  for the Phase [ADDRESS_870567] s of voting members chosen by [CONTACT_649541].  The DMSB operate s 
under the rules of an NIMH -approved charter.   
The DSMB will advise NIMH of its findings  and r eports will be shared with site IRBs, as required . We will 
be responsive to additional specific requests for data reports that may be requested by [CONTACT_4318].   
Confidentiality will be maintained during all phases of the DSMB review and deliberations.   
9.1.1 Schedule and Content of DSMB Reports  
The schedule for delivery o f the DSMB report s will be determined by [CONTACT_4318]; t hree (3) report s per 
year are expected. DSMB reports will be submitted via email to the COR and DSMB liaison.  
Elements that the DSMB needs for the interim and final reports will be clearly defined in advance  on a 
template developed in collaboration with the COR and approved by [CONTACT_4318]. The report will 
summarize overall trial progress as well as safety data for each site.  
9.2 Premature Termination or Suspension of Trial  
This trial may be prematurely termi nated if, in the opi[INVESTIGATOR_17439], NIMH, DSMB or IRB there is 
sufficient reasonable cause. Written notification, documenting the reason for study termination, will be 
provided to the PI [INVESTIGATOR_1238]/or NIMH by [CONTACT_51272]. Circumstances that may warrant termination 
include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to subjects.  
• Insufficient adherence to protocol requirements.  
• Failure to obtain sufficient follow -up data to evaluate the effectiveness  of the intervention.   
If the project is prematurely terminated or suspended, NIMH will promptly inform the 
investigators/institutions and the regulatory authorities of the termination or suspension and the 
reason(s) for the termination or suspension. The IRB will also be informed promptly and provided the 
reason(s) for the termination or suspension by [CONTACT_649542]/institution, as specified by 
[CONTACT_8146](s).  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870568] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
30 
 10 ASSESSMENT OF SAFETY  
10.1 Specification of Safe ty Parameters  
It is not feasible to report incidental adverse events (AEs) for this pragmatic trial . Study staff do not have 
contact [CONTACT_649543] . Only intervention arm patients have contact [CONTACT_85551] , 
resulting in an inability to compa re rates of incidental AEs between arms.   
We will compare the number and rate of emergency room and urgent care visits, inpatient 
hospi[INVESTIGATOR_602]  (psychiatric and non -psychiatric) , suicide attempt (fatal and non -fatal) , and deaths from 
all causes to monitor for potential harm to subjects . Comparisons of safety signals between arms will be 
made and reported to the DSMB [ADDRESS_870569] with intervention arm patient s/families  and will follow safe practice 
protocol if a patient or parent/guardian voluntarily discloses thoughts of self -harm . Study navigators do 
not assess suicide risk direct ly. See Appendix D of this protocol.  
Safe practice protocol use, actions taken, and resolution for each event will be tracked and summarized 
in reports for DSMB.  The events will not be considered adverse events because  there is no comparison 
data from th e control arm.  
The study therapi[INVESTIGATOR_649496] ’s clinical protocols if thoughts of self -harm are reported  by a patient .  
In addition to safe practice protocols, both navigator s and therapi[INVESTIGATOR_649497]. Standard 
procedures for reporting to Child Protective Services (CPS) will be followed should a subject voluntarily 
disclose child neglect or abuse.  CPS reportin g will not be tracked for study purposes.  
10.1.2  Adverse Events (AE) / Serious Adverse Events (SAE) and Reporting  
As noted above, reporting of incidental adverse events is not feasible for this pragmatic trial .  
The number and rate of events will be compared bet ween the two study arms in DSMB report s. 
• Emergency room and urgent care visits (SAE)  
• Inpatient hospi[INVESTIGATOR_602] (psychiatric and non -psychiatric) (SAE)  
• Suicide attempt (fatal and non -fatal) (SAE)  
• Death from all causes  (SAE)  
 
If study staff have contact [CONTACT_4490] a family and discover the patient died, the death will be reported to 
NIMH within 72 hours of discovery  as a serious adverse event . Other SAEs listed above about which 
study staff gain incidental knowledge will be reported i n the next DSMB report.  
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870570] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
31 
 10.1.3  Unanticipated Problems and Reporting  
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to 
subjects or others to include, in general, any incident, experience, or outcome that meets a ll three of 
the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the IRB -approved research protocol and 
informed consent document; and (b) the characteristics of the subject population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_9156]); and  
• Suggests that the research places subjects or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized.  
Incidents or events that meet th e OHRP criteria for unanticipated problems will be reported to the IRB 
and the NIMH DSMB.  Reporting of Unanticipated Problems to NIMH Program and the NIMH DSMB will 
be accomplished by [CONTACT_649544] N IMH.  
Per HHS regulations 46.103(b)(5), the “appropriate time frame for satisfying the requirement for prompt 
reporting will vary depending on the specific nature of the unanticipated problem, the nature of the 
research associated with the problem, and the  entity to which reports are to be submitted”.  We will 
apply the following recommended OHRP guidelines to satisfy prompt reporting requirements:  
• Unanticipated problems that are serious adverse events should be reported to the IRB within 1 
week of the inve stigator becoming aware of the event.  
• Any other unanticipated problem should be reported to the IRB within 2 weeks of the 
investigator becoming aware of the problem.  
• All unanticipated problems should be reported to appropriate institutional officials (as r equired 
by [CONTACT_17347]’s written reporting procedures), the supporting agency head (or designee), and 
OHRP within one month of the IRB’s receipt of the report of the problem from the investigator.  
Once submitted, NIMH will send a confirmation email to t he investigator within 2 business days. 
Unanticipated problems will be recorded in the data collection system throughout the trial.  
10.2 Halting Rules  
Study halting may occur as required by [CONTACT_1201], NIMH, or the NIMH DSMB.  The PI [INVESTIGATOR_649498].   
The study would not be halted early if the intervention was found to be protective  (i.e., si gnificantly 
lower rates of safety events in the intervention arm).  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870571] Number:  HHSN [ADDRESS_870572]; however, the NIMH reserves the 
right to conduct independent audits or clinical monitoring as necessary.  
See the next section for information about quality control and quality assurance, including quality 
management.  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870573] Number:  HHSN [ADDRESS_870574] manager at each study site.  
12.2 Quality Management  
A Quality Management Plan (QMP) will be created prior to fielding in order to establish the quality 
management guidelines for tasks related to the study.  At a minimum the quality management plan will 
be reviewed bi -annually by [CONTACT_649545] [INVESTIGATOR_79767].    
This QMP will be a living document that will be updated throughout the life of the project, as necessary, 
in order to document changes in scope or process.  The QMP will include a detailed description of 
quality management activities applicable to the study  at each site , including process documents, data 
collection, study record review, technical issues and resolution, essential documents, and staff training 
and qualifications. The QMP will include tools and checklists to be used in the quality management 
process, and describe when and how internal assessments will be summarized and reported to staff.  
12.[ADDRESS_870575] patient safety or study data integrity will be immediately reported 
to the K P Washington PI [INVESTIGATOR_1238] P M. T he DSMB will be informed within 5 business days of KP Washington 
becoming aware of a protocol deviation impacting patient safety or study data integrity . 
Sites will report other protocol deviations as outlined in the QMP , Site IRBs will be notified of deviations 
per local reporting requirements . The NIMH C ontracting Officer’s Representative  and NIMH DSMB will 
review protocol deviations in the tri -annual data reports . 
Events not considered protocol deviation s: Due to the pragmatic and encouragement design aspects of 
the study, t he failure of a provider or patient  to adhere to the protocol (e.g., by[CONTACT_649546] , 
not responding to request for active CAP consult, not following CAP recommendations, refusal or drop 
out from BH navigation or bridging, not closing a chart note in time for reviews to be conducted ), are 
not considered protocol deviation s. These uncontrolled and expected events are of scientific interest 
due to the pragmatic nature of the study.   
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870576] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
34 
 13 ETHICS /PROTECTION  OF HUMAN SUBJECTS  
13.[ADDRESS_870577]  
The investigator will ensure that this research study is conducted in full conformity with the principles 
set forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects 
of Research , as drafted by [CONTACT_286731] (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6 .  
13.[ADDRESS_870578] been tested and demonstrated effective elsewhere. No medications or other 
treatments are withheld or delayed. Prescribers are not mandated to accept the CAP’s 
recomme ndations and remain free to exercise their own clinical judgment. All the participating health 
systems already offer provider -to-provider consultation, car e navigation, and psychosocial therapy.  
13.2.1  Potential Risks  
Control  arm subjects receive no benefit from the study.  Potential risks are no different than usual care 
or usual employment. Breach of confidentiality is a possible risk of this research.  
For intervention arm patients , potential risks are no different than those experienced as part of other 
care navigation or psychosocial therapy offered as part of usual care. Some families /teens may not be 
comfortable participating in video -based bridging therapy  that may be offered by [CONTACT_1758] . This may be 
due in some cases to concerns abo ut confidentiality. Information will be provided to ensure 
families/teens understand these risks. They are free to refuse the video visits offered or to request 
phone -only visits (no video -conferencing).   
For i ntervention  arm providers , potential risks are  no different than usual employment insofar as 
employers are free to implement quality improvement programs and implement medication alerts.  
13.2.[ADDRESS_870579] is initiated  at each site .  Amendment s require review and approval 
by [CONTACT_649547] .   
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870580] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
35 
 13.4 Informed Consent Process  
Waivers of informed consent and assent will be obtained for this study at each clinical site , as granted by 
[CONTACT_32081] . Written informed c onsent /assent  will not be collected . Providers will be notified of the 
study via a communication sent prior to fielding. Families/teens are free to refuse navigation or bridging 
services at any time.  
The “Common Rule” for protection of re search participants (45 CFR 46.116d) lists specific requirements 
for waiver of the usual requirement of individual informed consent to participate in research.  Those 
criteria include: The research involves no more than minimal risk to the subjects – Accor ding to 45  CFR 
46.102:  “Minimal risk means that the probability and magnitude of harm or discomfort anticipated in 
the research are not greater in and of themselves than those ordinarily encountered in daily life or 
during the performance of routine physi cal or psychological examinations or tests.”  
Rationale for waiver of consent : 
• We do not believe that any of the components of the intervention expose providers or patients 
to greater than minimal risk. No treatment or intervention will be restricted or withheld ; 
providers maintain autonomy with respect to clinical decision making ;   
• No components of the intervention are experimental in nature. Consultation and case review, 
navigation, psychosocial therapy and medication alerts are all stand ard health care  provisions ; 
• Engagement in all study activities will be voluntary (e.g., medication alert  may be overridden, 
CAP recommendations may be disregarded, navigation and  bridging  therapy may be declined) ;  
• For control  arm providers and patients, the experience is identical to what would have been 
delivered had the study not occurred ;  
• The research is not practicab le without a waiver.  A trial limited to those who would actively 
consent to such a study would not be scientific ally valid;   
• When appropriate, providers and patients are given pertinent information  via staff 
communications  (providers) and the BH navigator (patients/families) ; 
• Patients and families are already in the study and randomized prior to being contact[CONTACT_649548].  Systematically excluding subjects after randomization would produce invalid research 
findings . It would be unethical to expose subjects to even minimal risk when such bias is known 
in advance.  
13.5 Exclusion of Women, Minorities, and Children (Special Populati ons)  
Individuals of any gender or racial/ethnic group may participate. Children ≥ 3 and < 18 years of age 
constitute the population of target patient -subjects .  Children diagnosed with psychotic disorder s 
including mania , autism spectrum disorder s or intellectual disabilities  will be excluded.   
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870581] Number:  HHSN [ADDRESS_870582] participant confidentiality.  This includes the following:  
• All project data will be maintained on secure, password protected servers at clinic al sites .  Only 
project staff need ing this information for their work will have access.  Members of the study 
team include Epic programmers from the delivery system ;  
• Limited data sets from subcontracted clinical sites will be transmitted from to the KPWHRI data 
coordinating center using a HIP AA-compliant secure FTP site ;  
• Participants will be identified using only subject ID  in any study analytic database(s) at each si te; 
• The protocol, documentation, data and all other identifying information will be held in strict 
confidence.  No information about the project will be released without prior approval of NIMH 
per the terms of the contract .  Authorized representatives of t he NIMH may inspect records, as 
needed.  
13.[ADDRESS_870583] no plans to retain identifiable information beyond this period.  If this plan changes, we will 
obtain appropriate IRB approval.  
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870584] Number:  HHSN [ADDRESS_870585]  are required to access d ata collected 
in electronic records . Any paper records generated with patient identifying information will be kept in 
locked filing cabinets in secured office buildings.  
Data sent to the KPWHRI data coordinating center will be transferred using a secure file transfer 
protocol (FTP)  site.  Data coordinating center files will be kept separately f rom other study files to 
maintain blinding of study staff working on other aspects of the project.  
No p articipant data shall be overwritten by [CONTACT_60551].  As necessary, variables may be recoded into 
new variables for analyses, so as to preserve the ori ginal record. All changes will be documented.  
Final datasets will be saved electronically, clearly labeled and stored in a secure project folder on the 
KPWHRI server accessible only to project staff.   
14.2 Data Capture Methods  
The majority of d ata for this pra gmatic study is captured electronically  in the site EMR, including the 
study enrollment log. Data entered into the navigator ’s personal  reporting workbench is also in Epic.  
TMH administrative metrics are captured by [CONTACT_484214][INVESTIGATOR_649499] a  de-identified electronic 
database . 
CAP treatment recommendations will be abstracted from Epic by [CONTACT_649549] -data entered into 
an electronic tracking system.  
All electronic records will be kept in a [ADDRESS_870586] 
unless consent to retain these files is granted by [CONTACT_1201].  Following this time, no other  records will be 
destro yed without the consent of NIMH . It is the responsibility of NIMH to inform the investigator when 
these documents no longer need to be retained . 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870587] Number:  HHSN [ADDRESS_870588] current version of this policy is available on the SUAY web portal site . 
(https://www.hcsrn.org/share/page/site/suay/dashboard ).  Topi[INVESTIGATOR_649500]:  
• Policy scope ;  
• SUAY publication committee ; 
• Use and confidentiality of data from participating sites ; 
• Decisions regarding author ship; 
• Coordination of the writing process ; 
• Tracking of publication progress ; 
• Acknowledgement of SUAY support and federal funding ; 
• Public access to products of NIH -funded research ; 
• Publicity regarding SUAY publications . 
The Steering Committee has developed and adopted a policy on the proposal and approval of new SUAY 
sub-projects. The most current version of this policy is available on the SUAY web portal site. 
(https://www.hcsrn.or g/share/page/site/suay/dashboard ).  Topi[INVESTIGATOR_649500]:  
• Policy scope  
• Categories (preparatory or pi[INVESTIGATOR_10299]; affiliated)  
• Procedures for proposing and approving preparatory or pi[INVESTIGATOR_649501]  
• Proced ures for proposing and supporting affiliated projects  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870589] Number:  HHSN [ADDRESS_870590] 3.5 years (December 25, 2017 – June 24, 2021).  The 
data sharing plan is incorporated by [CONTACT_649550]. Any changes to 
the data sharing plan must be pre -approved by [CONTACT_649551].  
The project is committed to sharing data created by [CONTACT_350405] , limited only by [CONTACT_649552]. Any datasets for public distribution 
(including to the National Database for Clinical Trials Related to Mental Illness) will be de -identified in 
compliance wi th HIPAA standard for de -identification.  
As noted in the contract ed statement of work, in Phase [ADDRESS_870591] -benefit analysis of the intervention.  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870592] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
40 
 17 LITERATURE   
1. Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic 
medications by [CONTACT_7683]. J Am Acad Child Adolesc Psychiatry. 2002;41( 5):514 -21. Epub 
2002/05/17.  
2. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of 
psychotropic medications to preschoolers. JAMA. 2000;283(8):1025 -30. Epub 2000/03/04.  
3. Zito JM, Safer DJ, DosReis S, Gardner JF, Magde r L, Soeken K, et al. Psychotropic practice 
patterns for youth: a 10 -year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17 -25. Epub 
2003/01/09.  
4. Zito JM, Safer DJ, Sai D, Gardner JF, Thomas D, Coombes P, et al. Psychotropic Medication 
Patterns Among  Youth in Foster Care. Pediatrics. 2008;121(1):e157 -e63.  
5. Crystal S, Olfson M, Huang C, Pi[INVESTIGATOR_35807] H, Gerhard T. Broadened Use Of Atypi[INVESTIGATOR_214414]: 
Safety, Effectiveness, And Policy Challenges. Health Affairs. 2009;28(5):w770 -w81.  
6. Olfson M, Crystal  S, Huang C, Gerhard T. Trends in antipsychotic drug use by [CONTACT_346480], 
privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13 -23. Epub 
2010/03/11.  
7. Penfold RB, Hunkeler EM, Madden JM, Cummings JR, Owen -Smith AA, Rossom RC, et al. Use of 
antipsychotic medications in pediatric populations: what do the data say? Curr Psychiatry Rep. 
2013;In Press.  
8. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National Trends in the Office -Based Treatment 
of Children, Adolescents, and Adults With Antipsychotics. Arch Gen Psychiatry. 2012:1 -10. Epub 
2012/08/08.  
9. Merikangas KR, He JP, Rapoport J, Vitiello B, Olfson M. Medication use in US youth with mental 
disorders. JAMA Pediatr. 2013;167(2):141 -8. Epub 2013/02/14.  
10. Andrade SE, Lo JC, Roblin D,  Fouayzi H, Connor DF, Penfold RB, et al. Antipsychotic medication 
use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6):1135 -41. Epub 
2011/11/23.  
11. Correll CU. Safety and tolerability of antipsychotic treatment in young patients with  
schizophrenia. J Clin Psychiatry. 2011;72(8):e26. Epub 2011/09/09.  
12. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic 
medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517 -35. 
Epub 20 11/12/15.  
13. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second -generation 
antipsychotics in children and adolescents: a Bayesian meta -analysis. J Clin Psychopharmacol. 
2012;32(3):309 -16. Epub 2012/05/01.  
14. Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, et al. Antipsychotics for 
children and young adults: a comparative effectiveness review. Pediatrics. 2012;129(3):e771 -84. 
Epub 2012/02/22.  
15. Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypi[INVESTIGATOR_649502]. Cochrane Database Syst Rev. 2012;9:CD008559. Epub 
2012/09/14.  
16. McKinney C, Renk K. Atypi[INVESTIGATOR_649503]: safety guidel ines and recommendations. Clin Psychol Rev. 2011;31(3):465 -
71. Epub 2010/12/07.  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870593] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
41 
 17. ABIM Foundation. American Psychiatric Association: Five Things Physicians and Patients Should 
Question. 2014 [March 22, 2015]; Available from: http://www.choosingwisely.org/doctor -
patient -lists/american -psychiatric -association/ . 
18. Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Mal one RP, Derivan A, et al. 
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. 
J Am Acad Child Adolesc Psychiatry. 2003;42(2):145 -61. Epub 2003/01/25.  
19. AACAP. Practice Parameter on the Use of Psychotropic Medica tion in Children and Adolescents. 
Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48(9):961 -73. 
20. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The [LOCATION_007] Children's 
Medication Algorithm Project: revi sion of the algorithm for pharmacotherapy of attention -
deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(6):642 -57. Epub 
2006/05/25.  
21. Steiner H, Remsing L, Work Group on Quality I. Practice parameter for the assessment and 
treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child 
Adolesc Psychiatry. 2007;46(1):126 -41. Epub 2007/01/02.  
22. Pappadopulos E, Rosato NS, Correll CU, Findling RL, Lucas J, Crystal S, et al. Experts' 
recommendations for tr eating maladaptive aggression in youth. J Child Adolesc 
Psychopharmacol. 2011;21(6):505 -15. Epub 2011/12/27.  
23. Findling RL, Drury S, Jensen PS, Rapoport J. Practice Parameter for the Use of Atypi[INVESTIGATOR_649504]. 2011:27.  
24. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and 
efficiency of guideline dissemination and implementation strategies. Health technology 
assessment (Winchester, England). 2004;8(6):iii -iv, 1-72. Epub 20 04/02/13.  
25. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, 
limitations, and harms of clinical guidelines. BMJ. 1999;318(7182):527 -30. Epub 1999/02/19.  
26. Eccles MP, Grimshaw JM, Shekelle P, Schunemann HJ, Woolf S. Developi[INVESTIGATOR_649505]: target audiences, identifying topi[INVESTIGATOR_649506], guideline group composition and 
functioning and conflicts of interest. Implement Sci. 2012;7:60. Epub 2012/07/06.  
27. Shekelle P, Woolf S, Grimshaw JM, S chunemann HJ, Eccles MP. Developi[INVESTIGATOR_649505]: reviewing, reporting, and publishing guidelines; updating guidelines; and the 
emerging issues of enhancing guideline implementability and accounting for comorbid 
conditions in guideline deve lopment. Implement Sci. 2012;7:62. Epub 2012/07/06.  
28. van Engen -Verheul MM, de Keizer NF, van der Veer SN, Kemps H, Reimer W, Jaspers M, et al. 
Evaluating the effect of a web -based quality improvement system with feedback and outreach 
visits on guideline  concordance in the field of cardiac rehabilitation: rationale and study 
protocol. Implement Sci. 2014;9(1):780. Epub 2015/01/01.  
29. Woolf S, Schunemann HJ, Eccles MP, Grimshaw JM, Shekelle P. Developi[INVESTIGATOR_649505]: types of evidence and  outcomes; values and economics, synthesis, grading, and 
presentation and deriving recommendations. Implement Sci. 2012;7:61. Epub 2012/07/06.  
30. Goud R, van Engen -Verheul M, de Keizer NF, Bal R, Hasman A, Hellemans IM, et al. The effect of 
computerized d ecision support on barriers to guideline implementation: a qualitative study in 
outpatient cardiac rehabilitation. Int J Med Inform. 2010;79(6):430 -7. Epub 2010/04/10.  
31. Grimshaw J, Eccles M, Tetroe J. Implementing clinical guidelines: current evidence a nd future 
implications. J Contin Educ Health Prof. 2004;[ADDRESS_870594] 1:S31 -7. Epub 2005/02/17.  
32. Soumerai SB. Are the peers peers? JAMA. 1995;273(7):523; author reply -4. Epub 1995/02/15.  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870595] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
42 
 33. Soumerai SB. Principles and uses of academic detailing to improve the management of 
psychiatric disorders. Int J Psychiatry Med. 1998;28(1):81 -96. Epub 1998/06/09.  
34. Soumerai SB, Avorn J. Physician education and cost containment. JAMA. 1985;253(13):1876 -7. 
Epub 1985/04/05.  
35. Soumerai SB, Avorn J. Economic and policy analysis of university -based drug "detailing". Med 
Care. 1986;24(4):313 -31. Epub 1986/04/01.  
36. Soumerai SB, Avorn J. Predictors of physician prescribing change in an educational experiment 
to improve medication use. Med Care. 1987;25(3):210 -21. Epub 1987 /03/01.  
37. Soumerai SB, Avorn J. Changing prescribing practices through individual continuing education. 
JAMA. 1987;257(4):487. Epub 1987/01/23.  
38. Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing') to improve 
clinical decisi on making. JAMA. 1990;263(4):549 -56. Epub 1990/01/26.  
39. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical 
analysis of the experimental literature. Milbank Q. 1989;67(2):268 -317. Epub 1989/01/01.  
40. Hilt RJ, Roma ire MA, McDonell MG, Sears JM, Krupski A, Thompson JN, et al. The Partnership 
Access Line: evaluating a child psychiatry consult program in Washington State. JAMA Pediatr. 
2013;167(2):162 -8. Epub 2012/12/19.  
41. Finnerty MT, Kealey E, Leckman -Westin E, Gupta N, White TM, Engel GM, et al. Long -term 
impact of web -based tools, leadership feedback, and policies on inpatient antipsychotic 
polypharmacy. Psychiatr Serv. 2011;62(10):1124 -6. Epub 2011/10/05.  
42. Schmid I, Burcu M, Zito JM. Medic aid prior authorization policies for pediatric use of 
antipsychotic medications. JAMA. 2015;313(9):966 -8. Epub 2015/03/04.  
43. Liang K -Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 
1986;73(1):13 -22. 
44. Zou G. A Modif ied Poisson Regression Approach to Prospective Studies with Binary Data. 
American Journal of Epi[INVESTIGATOR_623]. 2004;159(7):702 -6. 
45. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical 
trials of common outcomes. Am J  Epi[INVESTIGATOR_5541]. 2003;157(10):940 -3. Epub 2003/05/15.  
46. McCullagh P, Nelder JA. Generalized Linear Models. London, [LOCATION_006]: Chapman & Hall; 1989.  
47. Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson TM, Xie J, et al. Impact of atypi[INVESTIGATOR_649507] -deficit/hyperactivity disorder. Am J Manag 
Care. 2014;20(9):711 -21. Epub 2014/11/05.  
48. Stucke K, Kieser M. Sample size calculations for noninferiority trials with Poisson distributed 
count data. Biom J. 2013;55(2):203 -16. Ep ub 2013/02/13.  
49. Rubin DB. Multiple imputation for nonresponse in surveys. [LOCATION_001]: J Wiley & Sons; 1987.  
50. Rotnitzky A, Robins JM. Semiparametric regression estimation in the presence of dependent 
censoring. Biometrika. 1995;82(4):805 -20. 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870596] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
43 
 PROTOCOL APPENDICES  
These documents are relevant to , but not considered part of , the protocol.  Each clinical site will modif y, 
store , and obtain  IRB approval for the documents locally .  
Modifications to the protocol appendices by [CONTACT_649553] a protocol amendment . 
 
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870597] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
44 
 APPENDIX A: SCHEDULE OF EVENTS  
Event  Description  Timing   
Medication Alert and Enrollment Log 
Entry  The medication alert s fire in Epic during routine clinical encounters at which an 
antipsychotic is entered in Epic for a target patient. The patient is automatically 
added to the study enrollment log when the alert fires.  Day 0  
Alternatively : Active Order Entered in 
Epic and Enrollment Log Entry  The intervention arm provider directly orders a study service (i.e., navigation, 
bridging therapy, CAP consult) in Epic outside of the medication alert. The patient 
is automatically added to the study enrollment log when the order is e ntered.  Day 0  
Eligibility Validation  Study eligibility will be validated by [CONTACT_649554].  Target: Day [ADDRESS_870598] 
Review and Recommendations  The study CAP will complete case reviews and send the prescrib er 
recommendations within 3 business days of receiving notification of an eligible 
case. Consultation will be scheduled to occur within 10 business day when the 
study CAP requires more information and a consult wasn’t ordered.  Target: Day 0 -6 (review only 
or consult ordered)  
Target: Day 0 -13 (consult 
not ordered, discussion 
needed)  
Behavioral Health Navigator Outreach 
to Prescriber  The BH navigator will outreach the prescriber following CAP review. The navigator 
will also send periodic clinica lly relevant updates while his/her patient is receiving 
behavioral health navigation support.  Target: Day 3 -180  
(i.e., after the CAP’s review 
is completed)  
Behavioral Health Navigation for 
Patient/Teen  The navigator will contact [CONTACT_50634]/teens to offer u p to 6 months of BH navigation. 
Outreach will occur within 2 business days following CAP review. Teens/families 
accepting this extra support will be contact[CONTACT_649555]. Ad hoc contacts 
may be made if psychotherapy appointments are missed and not re scheduled.  Target: Day 6 -180 
(i.e., after BNH outreach to 
provider is complete)  
Bridging Therapy  Some teens/families will be offered bridging sessions with a study therapi[INVESTIGATOR_541]. Up to 
9 sessions may be offered.  (variable)  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870599] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
45 
 6 Month Follow Up Period  Data will be collected for the 6 month period after each eligible patient is added 
to the enrollment log. Analytic data will be derived from the EMR and other 
health plan data systems and study tracking systems.  Day 0 -180 
 
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870600] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
46 
  
APPENDIX B: PROVIDER ADVANCE COMMUNICATIONS AND MEDICATION ALERTS  
 
• Advance communication to intervention arm providers  
• Advance communication to control arm providers  
• Example text of intervention and control arm medication alerts  
  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870601] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
47 
  
APPENDIX C: SUAY CLINICAL GUIDANCE   
 
• Expert clinical guidance for the safer prescribing of antipsychotics to youth  
  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870602] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
48 
  
 
APPENDIX D: BH NAVIGATION  
 
• Behavioral health navigator script (s) for introductory calls  
• Behavioral health navigator script (s) for ongoing and final calls  
• Example staff messages to prescriber from behavioral health navigator  
• Example staff message to transition patient fro m bridging to ongoing psychotherapy  
• Behavioral health navigation safe practice protocol  
  
PHASE 3 TRIAL : Safer Use of Antipsychotics in Youth (SUAY)  Version [ADDRESS_870603] Number:  HHSN 2712016000002 C   
 ________________________________ ________________________________ ________________________________ ________   
 
 ________________________________ ________________________________ ____________________________   
49 
  
 
APPENDIX E: TELEMENTAL HEALTH BRIDGING  
These items apply only to study therapy sessions delivered via the telemental health modality. They do 
not apply to in -person sessions provided by a study therapi[INVESTIGATOR_77468].  
• Telemental health privacy and safety planning form  for video visits  
• Patient telemental health introductory and appointment reminder emails  
• Reminder telephone script for patient to return loaner device  for video visits  
 
 